Dutch AI Startup Raises €2.3 Million to Predict Post-Surgery Infections
Netherlands, Sunday, 1 March 2026.
Healthplus.ai secured funding to accelerate deployment of PERISCOPE®, an artificial intelligence system that forecasts patient-specific infection risks after operations and provides targeted prevention strategies for medical teams. The technology can save hospitals up to €4 million annually by reducing costly post-operative complications while decreasing staff workload pressure. Led by Elevating Capital and LUMO Labs, this investment enables the Netherlands-based company to expand across Europe and enter the US market, positioning AI as a critical tool in transforming healthcare delivery and improving patient outcomes.
Healthtech Innovation Addresses Critical Healthcare Challenge
This funding announcement represents a significant development in the healthtech sector, specifically targeting one of healthcare’s most pressing challenges: post-operative complications. Healthplus.ai operates as a MedTech scale-up focused on predictive healthcare solutions [1]. The company’s flagship technology, PERISCOPE®, represents an artificial intelligence system designed to predict patient-specific risks of post-operative infections while providing targeted action plans for healthcare teams [1]. Post-operative complications constitute a major cost center and source of workload pressure in hospitals, making this technology particularly valuable for healthcare systems under strain [1].
How PERISCOPE® Technology Functions
PERISCOPE® operates by integrating seamlessly with existing Electronic Patient Record (EPD) systems that serve the Dutch and broader European markets, including Epic, Oracle Cerner, and ChipSoft [1]. The system features automatic calibration capabilities, ensuring accurate predictions across different types of hospitals while maintaining compliance with all regulatory requirements [1]. This integration approach allows the technology to be rapidly adopted without requiring significant infrastructure changes. The AI system analyzes patient data to stratify risk levels, enabling doctors and nurses to create more precise treatment plans, intervene faster with high-risk patients, and safely discharge low-risk patients earlier [1]. This patient stratification capability directly supports faster recovery times, increases specialist efficiency, and reduces burden on healthcare systems [1].
Investment Details and Market Expansion Strategy
The €2.3 million funding round was led by Elevating Capital and LUMO Labs, with participation from Pathena Venture Capital, Leistone (Renza Family), and ROM InWest [1]. Elevating Capital, founded in 2001 and based in Delhi, India, has invested in 219 companies as of February 2026, with a portfolio including 7 unicorns, 30 IPOs, and 37 acquisitions [3]. The investment will be deployed to accelerate rollout across Europe and initiate expansion into the United States market [1]. Additionally, funds will support further development of AI risk models for all phases surrounding surgical operations [1]. Dr. Bart Geerts, CEO and founder of Healthplus.ai, emphasized the company’s focus on close collaboration with surgical specialists, nurses, and IT teams to ensure predictive insights genuinely improve patient outcomes [1].
Regional Innovation Ecosystem and Future Impact
Healthplus.ai exemplifies the innovation capabilities that North Holland region harbors, operating within an impressive Life Sciences & Health and AI ecosystem that includes research institutions, educational programs, campuses, startups, hospitals, and top-tier investors [1]. This ecosystem maintains international competitiveness and growing visibility [1]. ROM InWest, one of the participating investors, collaborates with Amsterdam knowledge institutions to organize and lead regional cooperation efforts [1]. Investment Manager Sara Schaafsma from ROM InWest noted that accurate patient stratification enables healthcare professionals to create better treatment plans, intervene more quickly with at-risk patients, and safely discharge low-risk patients earlier, ultimately contributing to a future-proof healthcare system [1]. The technology positions Amsterdam’s AI expertise—where the city leads European development—alongside clinical healthcare innovation [1]. [alert! ‘Timeline for US market entry not specified in sources’]